Does the media favor AVR or OBIO?

In the previous week, Anteris Technologies Global and Anteris Technologies Global both had 3 articles in the media. Orchestra BioMed's average media sentiment score of 1.33 beat Anteris Technologies Global's score of 1.06 indicating that Orchestra BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anteris Technologies Global 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Orchestra BioMed 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OBIO or DRTS?

In the previous week, Alpha Tau Medical had 4 more articles in the media than Orchestra BioMed. MarketBeat recorded 7 mentions for Alpha Tau Medical and 3 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 1.33 beat Alpha Tau Medical's score of -0.04 indicating that Orchestra BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alpha Tau Medical 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, OBIO or INMD?

InMode has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Orchestra BioMed $32.72M 7.76 -$52.70M -$0.97 N/A InMode $370.49M 2.27 $93.83M $1.36 10.75

Is OBIO or INMD more profitable?

InMode has a net margin of 23.27% compared to Orchestra BioMed's net margin of -166.96%. InMode's return on equity of 13.47% beat Orchestra BioMed's return on equity. Company Net Margins Return on Equity Return on Assets Orchestra BioMed -166.96% -157.46% -60.18% InMode 23.27% 13.47% 11.95%

Does the media favor OBIO or INMD?

In the previous week, InMode had 5 more articles in the media than Orchestra BioMed. MarketBeat recorded 8 mentions for InMode and 3 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 1.33 beat InMode's score of 0.68 indicating that Orchestra BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InMode 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, OBIO or BVS?

Bioventus has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Orchestra BioMed $32.72M 7.76 -$52.70M -$0.97 N/A Bioventus $568.09M 1.44 $22.73M $0.41 23.85

Does the media refer more to OBIO or BVS?

In the previous week, Orchestra BioMed had 1 more articles in the media than Bioventus. MarketBeat recorded 3 mentions for Orchestra BioMed and 2 mentions for Bioventus. Orchestra BioMed's average media sentiment score of 1.33 beat Bioventus' score of 0.72 indicating that Orchestra BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bioventus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, OBIO or SIBN?

SiBone has higher revenue and earnings than Orchestra BioMed. SiBone is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Orchestra BioMed $32.72M 7.76 -$52.70M -$0.97 N/A SiBone $200.93M 3.83 -$18.90M -$0.39 N/A

Is OBIO or SIBN more profitable?

SiBone has a net margin of -8.10% compared to Orchestra BioMed's net margin of -166.96%. SiBone's return on equity of -9.56% beat Orchestra BioMed's return on equity. Company Net Margins Return on Equity Return on Assets Orchestra BioMed -166.96% -157.46% -60.18% SiBone -8.10% -9.56% -7.06%

Orchestra BioMed (OBIO) Competitors

$4.24 +0.34 (+8.72%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$4.10 -0.14 (-3.40%)

As of 06/26/2026 07:50 PM Eastern

Compare

OBIO vs. AVR, DRTS, INMD, BVS, and SIBN

Should you buy Orchestra BioMed stock or one of its competitors? MarketBeat compares Orchestra BioMed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Orchestra BioMed include Anteris Technologies Global (AVR), Alpha Tau Medical (DRTS), InMode (INMD), Bioventus (BVS), and SiBone (SIBN). These companies are all part of the "medical equipment" industry.

How does Orchestra BioMed compare to Anteris Technologies Global?

Anteris Technologies Global (NASDAQ:AVR) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

53.2% of Orchestra BioMed shares are owned by institutional investors. 4.5% of Anteris Technologies Global shares are owned by company insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Anteris Technologies Global currently has a consensus target price of $16.00, indicating a potential upside of 65.56%. Orchestra BioMed has a consensus target price of $13.60, indicating a potential upside of 220.75%. Given Orchestra BioMed's higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than Anteris Technologies Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anteris Technologies Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Orchestra BioMed has a net margin of -166.96% compared to Anteris Technologies Global's net margin of -5,148.78%. Anteris Technologies Global's return on equity of -124.76% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anteris Technologies Global	-5,148.78%	-124.76%	-101.21%
Orchestra BioMed	-166.96%	-157.46%	-60.18%

Anteris Technologies Global has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

In the previous week, Anteris Technologies Global and Anteris Technologies Global both had 3 articles in the media. Orchestra BioMed's average media sentiment score of 1.33 beat Anteris Technologies Global's score of 1.06 indicating that Orchestra BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anteris Technologies Global	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Orchestra BioMed	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Orchestra BioMed has higher revenue and earnings than Anteris Technologies Global. Orchestra BioMed is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anteris Technologies Global	$1.91M	492.51	-$94.14M	-$2.23	N/A
Orchestra BioMed	$32.72M	7.76	-$52.70M	-$0.97	N/A

Summary

Orchestra BioMed beats Anteris Technologies Global on 10 of the 15 factors compared between the two stocks.

How does Orchestra BioMed compare to Alpha Tau Medical?

Orchestra BioMed (NASDAQ:OBIO) and Alpha Tau Medical (NASDAQ:DRTS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 2.7% of Alpha Tau Medical shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by company insiders. Comparatively, 39.5% of Alpha Tau Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Orchestra BioMed has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Alpha Tau Medical has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market.

Alpha Tau Medical has a net margin of 0.00% compared to Orchestra BioMed's net margin of -166.96%. Alpha Tau Medical's return on equity of -73.23% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-166.96%	-157.46%	-60.18%
Alpha Tau Medical	N/A	-73.23%	-52.90%

In the previous week, Alpha Tau Medical had 4 more articles in the media than Orchestra BioMed. MarketBeat recorded 7 mentions for Alpha Tau Medical and 3 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 1.33 beat Alpha Tau Medical's score of -0.04 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alpha Tau Medical	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alpha Tau Medical has lower revenue, but higher earnings than Orchestra BioMed. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$32.72M	7.76	-$52.70M	-$0.97	N/A
Alpha Tau Medical	N/A	N/A	-$42.63M	-$0.67	N/A

Orchestra BioMed currently has a consensus price target of $13.60, suggesting a potential upside of 220.75%. Alpha Tau Medical has a consensus price target of $12.60, suggesting a potential upside of 15.81%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, research analysts clearly believe Orchestra BioMed is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Alpha Tau Medical	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Alpha Tau Medical beats Orchestra BioMed on 8 of the 15 factors compared between the two stocks.

How does Orchestra BioMed compare to InMode?

Orchestra BioMed (NASDAQ:OBIO) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

In the previous week, InMode had 5 more articles in the media than Orchestra BioMed. MarketBeat recorded 8 mentions for InMode and 3 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 1.33 beat InMode's score of 0.68 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InMode	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Orchestra BioMed has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, InMode has a beta of 1.94, indicating that its share price is 94% more volatile than the broader market.

53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by insiders. Comparatively, 6.9% of InMode shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Orchestra BioMed presently has a consensus target price of $13.60, suggesting a potential upside of 220.75%. InMode has a consensus target price of $16.00, suggesting a potential upside of 9.39%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, equities research analysts clearly believe Orchestra BioMed is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

InMode has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$32.72M	7.76	-$52.70M	-$0.97	N/A
InMode	$370.49M	2.27	$93.83M	$1.36	10.75

InMode has a net margin of 23.27% compared to Orchestra BioMed's net margin of -166.96%. InMode's return on equity of 13.47% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-166.96%	-157.46%	-60.18%
InMode	23.27%	13.47%	11.95%

Summary

InMode beats Orchestra BioMed on 10 of the 16 factors compared between the two stocks.

How does Orchestra BioMed compare to Bioventus?

Orchestra BioMed (NASDAQ:OBIO) and Bioventus (NASDAQ:BVS) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Orchestra BioMed currently has a consensus price target of $13.60, suggesting a potential upside of 220.75%. Bioventus has a consensus price target of $14.20, suggesting a potential upside of 45.19%. Given Orchestra BioMed's higher possible upside, research analysts clearly believe Orchestra BioMed is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Orchestra BioMed had 1 more articles in the media than Bioventus. MarketBeat recorded 3 mentions for Orchestra BioMed and 2 mentions for Bioventus. Orchestra BioMed's average media sentiment score of 1.33 beat Bioventus' score of 0.72 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bioventus has a net margin of 4.94% compared to Orchestra BioMed's net margin of -166.96%. Bioventus' return on equity of 29.97% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-166.96%	-157.46%	-60.18%
Bioventus	4.94%	29.97%	9.52%

53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by company insiders. Comparatively, 33.0% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Orchestra BioMed has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Bioventus has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

Bioventus has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$32.72M	7.76	-$52.70M	-$0.97	N/A
Bioventus	$568.09M	1.44	$22.73M	$0.41	23.85

Summary

Bioventus beats Orchestra BioMed on 12 of the 17 factors compared between the two stocks.

How does Orchestra BioMed compare to SiBone?

Orchestra BioMed (NASDAQ:OBIO) and SiBone (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

53.2% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by company insiders. Comparatively, 4.0% of SiBone shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Orchestra BioMed presently has a consensus target price of $13.60, suggesting a potential upside of 220.75%. SiBone has a consensus target price of $23.00, suggesting a potential upside of 32.72%. Given Orchestra BioMed's higher possible upside, research analysts clearly believe Orchestra BioMed is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

SiBone has higher revenue and earnings than Orchestra BioMed. SiBone is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$32.72M	7.76	-$52.70M	-$0.97	N/A
SiBone	$200.93M	3.83	-$18.90M	-$0.39	N/A

In the previous week, Orchestra BioMed had 2 more articles in the media than SiBone. MarketBeat recorded 3 mentions for Orchestra BioMed and 1 mentions for SiBone. Orchestra BioMed's average media sentiment score of 1.33 beat SiBone's score of 0.93 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company	Overall Sentiment
Orchestra BioMed	Positive
SiBone	Positive

SiBone has a net margin of -8.10% compared to Orchestra BioMed's net margin of -166.96%. SiBone's return on equity of -9.56% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-166.96%	-157.46%	-60.18%
SiBone	-8.10%	-9.56%	-7.06%

Orchestra BioMed has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, SiBone has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

Summary

SiBone beats Orchestra BioMed on 10 of the 16 factors compared between the two stocks.

Get Orchestra BioMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBIO vs. The Competition

Export

Metric	Orchestra BioMed	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$233.54M	$3.55B	$6.70B	$12.22B
Dividend Yield	N/A	2.25%	2.67%	6.12%
P/E Ratio	-4.37	21.56	25.76	24.17
Price / Sales	7.76	335.68	556.00	98.91
Price / Cash	N/A	137.38	46.99	54.37
Price / Book	4.46	8.34	10.77	6.35
Net Income	-$52.70M	$23.91M	$3.57B	$337.63M
7 Day Performance	6.27%	6.85%	3.17%	0.43%
1 Month Performance	7.34%	4.25%	1.86%	0.14%
1 Year Performance	52.52%	65.92%	34.39%	27.64%

Orchestra BioMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBIO Orchestra BioMed	4.1068 of 5 stars	$4.24 +8.7%	$13.60 +220.8%	+42.3%	$233.54M	$32.72M	N/A	4	News Coverage Positive News High Trading Volume
AVR Anteris Technologies Global	3.4315 of 5 stars	$10.30 +7.4%	$16.00 +55.4%	+141.6%	$933.51M	$1.91M	N/A	138
DRTS Alpha Tau Medical	2.6975 of 5 stars	$9.99 +1.9%	$12.60 +26.2%	+260.3%	$899.20M	N/A	N/A	80	Insider Trade
INMD InMode	1.5909 of 5 stars	$14.86 +11.3%	$16.00 +7.7%	+4.0%	$855.09M	$374.64M	10.94	480	News Coverage Positive News
BVS Bioventus	4.1334 of 5 stars	$9.40 +6.9%	$14.20 +51.1%	N/A	$734.27M	$568.09M	22.66	1,200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OBIO) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Orchestra BioMed (OBIO) Competitors

OBIO vs. AVR, DRTS, INMD, BVS, and SIBN

How does Orchestra BioMed compare to Anteris Technologies Global?

Summary

How does Orchestra BioMed compare to Alpha Tau Medical?

Summary

How does Orchestra BioMed compare to InMode?

Summary

How does Orchestra BioMed compare to Bioventus?

Summary

How does Orchestra BioMed compare to SiBone?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBIO vs. The Competition

Orchestra BioMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Orchestra BioMed (OBIO) Competitors

OBIO vs. AVR, DRTS, INMD, BVS, and SIBN

How does Orchestra BioMed compare to Anteris Technologies Global?

Do insiders and institutionals believe in AVR or OBIO?

Do analysts recommend AVR or OBIO?

Is AVR or OBIO more profitable?

Which has more volatility & risk, AVR or OBIO?

Does the media favor AVR or OBIO?

Which has preferable earnings & valuation, AVR or OBIO?

Summary

How does Orchestra BioMed compare to Alpha Tau Medical?

Do insiders & institutionals hold more shares of OBIO or DRTS?

Which has more volatility and risk, OBIO or DRTS?

Is OBIO or DRTS more profitable?

Does the media prefer OBIO or DRTS?

Which has preferable valuation & earnings, OBIO or DRTS?

Do analysts prefer OBIO or DRTS?

Summary

How does Orchestra BioMed compare to InMode?

Does the media favor OBIO or INMD?

Which has more volatility & risk, OBIO or INMD?

Do insiders and institutionals have more ownership in OBIO or INMD?

Do analysts prefer OBIO or INMD?

Which has higher valuation & earnings, OBIO or INMD?

Is OBIO or INMD more profitable?

Summary

How does Orchestra BioMed compare to Bioventus?

Do analysts prefer OBIO or BVS?

Does the media refer more to OBIO or BVS?

Is OBIO or BVS more profitable?

Do insiders & institutionals have more ownership in OBIO or BVS?

Which has more risk and volatility, OBIO or BVS?

Which has preferable earnings and valuation, OBIO or BVS?

Summary

How does Orchestra BioMed compare to SiBone?

Do institutionals & insiders hold more shares of OBIO or SIBN?

Do analysts recommend OBIO or SIBN?

Which has preferable earnings and valuation, OBIO or SIBN?

Does the media favor OBIO or SIBN?

Is OBIO or SIBN more profitable?

Which has more risk & volatility, OBIO or SIBN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBIO vs. The Competition

Orchestra BioMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools